Post‐Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma
International Journal of Urology · 2026
DOI: 10.1111/iju.70549 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Hiro-Omi Kanayama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kawashima Hospital, Tokushima, Japan. Hauptthemen laut MEDLINE: Pyridines, Anilides, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company and Limited.
Abstract (Originalsprache)
Objectives
This post‐marketing surveillance study evaluated the real‐world safety and effectiveness of cabozantinib in Japanese patients with advanced renal cell carcinoma (aRCC).
Methods
This prospective, observational study enrolled patients with histologically or cytologically confirmed aRCC across 102 sites in Japan. Patients received cabozantinib as monotherapy or in combination with nivolumab according to approved label regimens and were monitored for 26 weeks. The primary outcome was the incidence of adverse drug reactions (ADRs) related to hepatic failure/dysfunction and pancreatitis. Secondary outcomes included grade 3 or higher ADRs, treatment discontinuation due to ADRs, and investigator‐assessed objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Results
Of 388 enrolled patients, 385 were included in the analysis (median age, 71.0 years; 70.1% men). Patients receiving monotherapy ( n = 322) and those receiving combination therapy ( n = 63) reported ADRs related to hepatic failure/dysfunction (16.15% and 25.40%), pancreatitis‐related ADRs (2.80% and 4.76%), grade 3 or higher ADRs (24.84% and 38.10%), and ADRs leading to treatment discontinuation (13.98% and 30.16%), respectively. The most common grade 3 or higher ADRs were hypertension (3.73%), reduced appetite (3.11%), and hand‐foot syndrome (3.11%) in the monotherapy group, and diarrhea (4.76%) in the combination therapy group. The ORR was 32.9% for patients receiving monotherapy and 41.3% for those receiving combination therapy.
Conclusions
Cabozantinib, as monotherapy or in combination with nivolumab, demonstrated safety and effectiveness in Japanese patients with aRCC in real‐world settings, consistent with previous literature. No new safety concerns were identified. These findings support the use of cabozantinib‐based regimens in Japanese clinical practice. Trail Registration Japan Registry of Clinical Trials (JRCT), registration number: jRCT2031210003.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kawashima Hospital, Tokushima, Japan.
- Statistical & Quantitative Sciences, R&D Data & Quantitative Sciences, Takeda Pharmaceutical Co. Ltd., Osaka, Japan.
- Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Co. Ltd., Tokyo, Japan.
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Masatoshi Eto
Förderung
- Takeda Pharmaceutical Company and Limited
Zitieren
APA
Kanayama, H. O., Kuroda, S., Osaka, T., & Eto, M. (2026). Post‐Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.70549
Vancouver
Kanayama HO, Kuroda S, Osaka T, Eto M. Post‐Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma. International Journal of Urology. 2026. doi:10.1111/iju.70549
BibTeX
@article{Kanayama2026,
author = {Kanayama, Hiro-Omi and Kuroda, Shingo and Osaka, Tsuyoshi and Eto, Masatoshi},
title = {Post‐Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70549}
}
EUVIMED